Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab combined with RMA in newly diagnosed PCNSL
NCT05347641Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in primary central nervous system lymphoma (PCNSL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 2-year Progression-Free Survival rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05347641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347641.